General anesthetics

DGAP-News: PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA

Thursday, November 19, 2020 - 10:07pm

- Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol

Key Points: 
  • - Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol
    - EU Phase III program completed; data to serve as basis for MAA submission in general anesthesia
    Aachen (Germany), 19 November 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces positive topline data from the pivotal remimazolam EU Phase III trial in general anesthesia.
  • Assuming approval in procedural sedation, PAION plans to submit an extension of the marketing authorization for remimazolam for general anesthesia.
  • In addition to procedural sedation and general anesthesia, based on positive Phase II study results, ICU sedation is another possible indication for remimazolam.
  • In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation.

DGAP-News: PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020

Wednesday, November 11, 2020 - 7:01am

In the U.S., the FDA (Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.

Key Points: 
  • In the U.S., the FDA (Food & Drug Administration) granted market approval of BYFAVOTM (remimazolam) for procedural sedation in July 2020.
  • In October 2020, the Drug Enforcement Administration (DEA) designated BYFAVO(TM) as a Schedule IV medicine, which was a prerequisite for launch.
  • The overall evaluation of opportunities and risks has not changed significantly in the first nine months of 2020.
  • PAION confirms its financial outlook for the current fiscal year announced on 12 August 2020 with the publication of the half-year results for 2020.

China Sevoflurane Markets Report 2015-2019 & 2020-2024: Major Players are Shanghai Hengrui Pharmaceutical, Maruishi, Baxter and Lunan Better Pharmaceutical

Monday, November 9, 2020 - 2:45pm

DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • In 2007 and 2008, the Chinese government approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China.
  • According to this market research, the major market shareholders in China are Shanghai Hengrui Pharmaceutical Co., Ltd., Maruishi, Baxter and Lunan Better Pharmaceutical Co., Ltd.
  • 2 Analysis of Sevoflurane Sales in China, 2015-2019
    2.1 Sales Value of Sevoflurane in China, 2015-2019
    2.1.1 Overall Sales value of Sevoflurane in China, 2015-2019
    2.1.2 Sales Value of Sevoflurane in different regions of China, 2015-2019
    2.2 Sales Volume of Sevoflurane in China, 2015-2019
    2.2.1 Overall Sales Volume of Sevoflurane in China, 2015-2019
    2.2.2 Sales Volume of Sevoflurane in Different Regions of China, 2015-2019
    2.3 Market Share of Sevoflurane by Dosage Form in China, 2015-2019
    3 Major Sevoflurane Manufacturers in Chinese Market, 2015-2020
    3.1 Shanghai Hengrui Pharmaceutical Co., Ltd.
    3.1.1 Profile of Shanghai Hengrui Pharmaceutical Co., Ltd.
    3.1.2 Sales value and volume of Shanghai Hengrui Pharmaceutical Co., Ltd.'s sevoflurane in China 2019-2020
    3.2.1 Profile of Maruishi Pharmaceutical Co., Ltd.
    3.3 Lunan Better Pharmaceutical Co., Ltd.
    3.3.1 Profile of Lunan Better Pharmaceutical Co., Ltd.
    3.3.2 Sales value and volume of Lunan Better Pharmaceutical Co., Ltd.'s sevoflurane in China 2019-2020
    4 Reference Price of Sevoflurane in Different Regions of China, 2019-2020
    4.2 Average Price of Shanghai Hengrui Pharmaceutical Co., Ltd.'s Sevoflurane in China
    4.2.2 Prices of Shanghai Hengrui Pharmaceutical Co., Ltd.'s Sevoflurane in different regions of China
    4.4 Average Price of Lunan Better Pharmaceutical Co., Ltd.'s Sevoflurane in China
    4.4.2 Prices of Lunan Better Pharmaceutical Co., Ltd.'s Sevoflurane in different regions of China
    5 Prospects of Sevoflurane in China, 2020-2024
    Chart Sales Value of Sevoflurane in China, 2015-2019
    Chart Sales volume of Sevoflurane in China, 2015-2019
    Chart Market Share of Top 6 Sevoflurane Manufacturers in Sales Value, 2015-2019
    Chart Market Share and Sales Value of Maruishi in China, 2015-2019
    Chart Market Share and Sales Value of Shanghai Hengrui Pharmaceutical in China, 2015-2019
    Chart Market Share and Sales Value of BAXTER in China, 2015-2019
    Chart Price of Maruishi's Sevoflurane in Different Regions of China, 2019-2020
    Chart Price of Shanghai Hengrui Pharmaceutical's Sevoflurane in Different Regions of China, 2019-2020
    Chart Forecast on Sevoflurane Market Size in China, 2020-2024
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder

Wednesday, November 4, 2020 - 3:30pm

The allowance is based on US Patent Application 15/987,933 entitled: Formulations for Treatment of Post-Traumatic Stress Disorder.

Key Points: 
  • The allowance is based on US Patent Application 15/987,933 entitled: Formulations for Treatment of Post-Traumatic Stress Disorder.
  • The inventor, Prof. Daniel Javitt, M.D., Ph.D., is co-founder of NeuroRx and was among the first to report the role of the NMDA receptor in psychiatric disease.
  • The treatment consists of the administration of ketamine, a potent NMDA receptor antagonist, to a subject in need followed by the administration of a pharmaceutical formulation comprising of different dosages of D-cycloserine and an anti-depression or anti-psychosis agent.
  • NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD.

Investigation Report on Sevoflurane Markets in China, 2015-2019 & 2020-2024 - ResearchAndMarkets.com

Tuesday, November 3, 2020 - 10:35am

The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on Sevoflurane in China, 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.
  • According to this analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently, Abbott holds a very small market share.
  • The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States.

Avesta Ketamine and Wellness is Opening a Second Location in McLean Virginia November 2020

Friday, October 16, 2020 - 9:00pm

MCLEAN, Va., Oct. 16, 2020 /PRNewswire-PRWeb/ --Avesta Ketamine and Wellness is excited to announce the opening of their second location in McLean Virginia November 2020.

Key Points: 
  • MCLEAN, Va., Oct. 16, 2020 /PRNewswire-PRWeb/ --Avesta Ketamine and Wellness is excited to announce the opening of their second location in McLean Virginia November 2020.
  • Avesta Ketamine and Wellness is a provider of IV Ketamine Infusions for the treatment of depression, anxiety, PTSD, migraines, fibromyalgia, and chronic pain.
  • Dr. Ladan Eshkevari is the lead clinician at Avesta Ketamine and Wellness and Program Director and Associate Professor in the Doctor of Nurse Anesthesia Practice program at Georgetown University.
  • If you would like to learn more about Avesta Ketamine and Wellness, please visit http://www.avestaketaminewellness.com or call 703-201-7767.

Diprivan® (Propofol) Injectable Emulsion, USP is First Product Available in Fresenius Kabi +RFID™ Portfolio of Smart-Labeled Medications

Thursday, October 8, 2020 - 2:00pm

The first +RFID smart-labeled product, Diprivan (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, is now available in the United States.

Key Points: 
  • The first +RFID smart-labeled product, Diprivan (Propofol) 200 mg per 20 mL (10 mg per mL) Injectable Emulsion, USP, is now available in the United States.
  • View the full release here: https://www.businesswire.com/news/home/20201008005150/en/
    Fresenius Kabi introduced its first +RFID smart-labeled product - Diprivan (propofol) in a 20 mL vial.
  • In 2021, Fresenius Kabi expects to add more than 20 medicines to its +RFID portfolio in the United States.
  • This Important Safety Information does not include all the information needed to use DIPRIVAN (Propofol), Injectable Emulsion, USP safely and effectively.

NY Ketamine Infusions, New York City's Premier Ketamine Depression Clinic, Brings Breakthrough Treatments to Long Island

Tuesday, September 22, 2020 - 2:00pm

In multiple studies performed over the past 20 years by researchers at Yale University, Mt.

Key Points: 
  • In multiple studies performed over the past 20 years by researchers at Yale University, Mt.
  • Citing a recent study, Cleveland Clinic noted that "within 24 hours of receiving ketamine, 70 percent of patients with treatment-resistant depression saw an improvement in symptoms."
  • NY Ketamine Infusions has been helping patients who have not responded to either traditional psychiatric medications or psycho-therapyoften with tremendous, life-changing results.
  • "In our new Long Island office, we promise to provide the highest level of individualized care to each of our patients.

Stevanato Group And Bexson Biomedical Announce Collaboration To Develop A Customized Wearable Ketamine Delivery Device

Monday, September 21, 2020 - 8:41pm

Stevanato Group's device is designed to enable dynamic and convenient subcutaneous delivery for patients, compared to current ketamine infusions that have a high procedural burden and high cost.

Key Points: 
  • Stevanato Group's device is designed to enable dynamic and convenient subcutaneous delivery for patients, compared to current ketamine infusions that have a high procedural burden and high cost.
  • Ketamine, which blocks a receptor that is fundamental in pain signaling, is already being used by doctors through in-office infusions.
  • "And beyond pain management, this partnership will create a true ketamine delivery platform that can be leveraged for a large number of future indications."
  • Established in 1949, Stevanato Group is the world's largest, privately-owned designer and producer of glass primary packaging for the pharmaceutical industry.

Ethylene Oxide Markets in China Forecast to Grow by 8% by 2023

Tuesday, August 25, 2020 - 12:30pm

DUBLIN, Aug. 25, 2020 /PRNewswire/ -- The "Ethylene Oxide Markets in China" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 25, 2020 /PRNewswire/ -- The "Ethylene Oxide Markets in China" report has been added to ResearchAndMarkets.com's offering.
  • China's demand for Ethylene Oxide has grown at a fast pace in the past decade.
  • The primary and secondary research was done in China in order to access up-to-date government regulations, market information and industry data.
  • If you want to expand your business or sell your products in China, this research report provides the insights and projections into Chinese markets necessary for you to do so.